2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 130 filers reported holding 2SEVENTY BIO INC in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,055,754 | -42.1% | 779,529 | +49.5% | 0.02% | -40.0% |
| Q2 2023 | $5,275,192 | +345.2% | 521,264 | +348.7% | 0.03% | +328.6% |
| Q1 2023 | $1,185,036 | +9.9% | 116,180 | +0.9% | 0.01% | 0.0% |
| Q4 2022 | $1,078,628 | -28.1% | 115,115 | +11.7% | 0.01% | -41.7% |
| Q3 2022 | $1,500,000 | – | 103,068 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Newtyn Management, LLC | 1,587,805 | $27,088,000 | 6.49% |
| CHI Advisors LLC | 819,672 | $13,984,000 | 5.95% |
| Madison Avenue Partners, LP | 896,972 | $15,302,342,000 | 2.86% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $24,036,000 | 2.33% |
| EcoR1 Capital, LLC | 3,495,943 | $59,641,000 | 1.87% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $5,118,000 | 1.02% |
| CVI Holdings, LLC | 819,672 | $13,984,000 | 0.92% |
| ARMISTICE CAPITAL, LLC | 2,000,000 | $34,120,000 | 0.66% |
| Altium Capital Management LP | 115,000 | $1,962,000 | 0.66% |
| Casdin Capital, LLC | 614,754 | $10,488,000 | 0.47% |